Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

Publication

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

Journal Paper/Review - Apr 12, 2022

Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali PA, Ceresoli G L, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y

Mark, M

Rusakiewicz, S

Früh, M

Hayoz, S

Grosso, F

Pless, M

Zucali, PA

Ceresoli, G L

Maconi, A

Schneider, M

Froesch, P

Tarussio, D

Benedetti, F

Dagher, J

Kandalaft, L

von Moos, R

Tissot-Renaud, S

Schmid, S

Metaxas, Y